| NSCLC | Non-small cell lung cancer |
| RTK | Receptor tyrosine kinase |
| RAS | Rat sarcoma virus |
| RAF | Serine/threonine-protein kinase |
| KRAS | Kirsten rat sarcoma |
| EGFR | Epidermal growth factor receptor |
| BRAF | v-Raf murine sarcoma viral oncogene homolog B |
| MET | Mesenchymal-epithelial transition |
| PI3K | Phosphoinositide 3-kinase |
| HGF | Hepatocyte growth factor |
| MAPK | Mitogen-activated protein kinase |
| FISH | Fluorescent in-situ hybridization |
| TKI | Tyrosine-kinase inhibitors |
| PFS | Progression-free survival |
| OS | Overall survival |
| ORR | Overall response rate |
| HR | Hazard ratio |
| CI | Confidence interval |
| IV | Intravenous |
| IHC | Immunohistochemistry |
| DCR | Disease control rate |
| DOR | Duration of response |
| CNS | Central nervous system |